ArticleSisli Etfal Hastanesi tip bulteni2025
Depression and Anxiety in Parkinson's Disease: Prevalence and Associated Risk Factors.
Article in Sisli Etfal Hastanesi tip bulteni, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Parkinson's disease (PD) is a neurodegenerative disorder with both motor and non-motor symptoms, including depression and anxiety, which significantly impact patients' quality of life. The predictors of these psychiatric symptoms remain incompletely understood. This study aims to evaluate the prevalence and potential predictors of depression and anxiety in PD. Methods: A prospective study was conducted on 99 idiopathic PD patients. Depression and anxiety were assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) scale. A range of clinical and demographic variables, including motor symptoms, sleep disturbances, and quality of life, were analyzed using regression models. Results: Of the patients, 57.5% had depression, 48.4% had anxiety, and 36.3% had both. Significant predictors of depression included the use of apomorphine, which was associated with lower PHQ-9 scores (p=0.031), and the presence of restless legs syndrome (RLS), which was linked to higher depression scores (p=0.037). For anxiety, younger age was a significant predictor (p=0.007). Both depression and anxiety scores correlated with lower quality of life (p<0.001 for both). Conclusion: This study highlights the high prevalence of depression and anxiety in PD, with significant predictors including RLS for depression and younger age for anxiety. Apomorphine use appears protective against depression. Both depression and anxiety disrupt quality of life. These findings underscore the importance of routine psychiatric screening and comprehensive management of depression and anxiety in PD, aiming to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.